Loading organizations...
§ Private Profile · San Diego, CA, USA
Libra Therapeutics is a technology company.
Libra Therapeutics develops novel therapeutics designed to restore cellular balance in neurodegenerative diseases. The company’s core strategy involves improving lysosomal function and increasing autophagy, processes critical for cellular waste removal, with the aim of halting disease progression. This approach targets underlying cellular dysfunction common across various neurological conditions.
The company emerged to address the significant unmet needs within neurodegenerative disease treatment. While the foundational science originated from Axxam, an Italian discovery research organization, Isaac Veinbergs served as the founding CEO. The company was established with the insight that modulating lysosomal pathways could offer a broadly applicable therapeutic strategy to combat these complex and debilitating conditions.
Libra Therapeutics focuses on delivering disease-modifying treatments to patients afflicted with a range of neurodegenerative disorders. The company’s vision is to advance a therapeutic approach that broadly impacts these conditions, ultimately providing meaningful solutions and improving the lives of patients and their families by targeting fundamental disease mechanisms.
Libra Therapeutics has raised $29.0M across 1 funding round.
Libra Therapeutics has raised $29.0M in total across 1 funding round.
Libra Therapeutics has raised $29.0M across 1 funding round. Most recently, it raised $29.0M Series A in September 2020.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Sep 1, 2020 | $29M Series A | Martin Heidecker, Henning Steinhagen, Saints Capital | AMR Action Fund, Mission BioCapital, Dolby Family Ventures, Sixty Degree Capital, Yonjin Capital | Announced |
Libra Therapeutics has raised $29.0M in total across 1 funding round.
Libra Therapeutics's investors include Martin Heidecker, Henning Steinhagen, Saints Capital, AMR Action Fund, Mission BioCapital, Dolby Family Ventures, Sixty Degree Capital, Yonjin Capital.
Libra Therapeutics is a San Diego-based biotechnology company developing novel small molecule therapeutics to restore cellular balance in neurodegenerative diseases such as ALS, frontotemporal dementia, Alzheimer's, Parkinson's, and Huntington's.[1][2][3] Its lead program targets TRPML1 to enhance lysosomal function and autophagy, clearing toxic proteins and reducing neurotoxic protein production, with Phase 1 clinical trials on track for 2025; the pipeline includes three small molecule programs serving patients with CNS and peripheral degenerative disorders.[1][2][3] Operating as a fully virtual company without in-house labs, Libra leverages a global network of contract research organizations (CROs) for all R&D, enabling efficient progression from screening to IND-enabling studies while raising $29M in Series A funding.[1][2]
Founded in 2019 (with some sources noting establishment in 2020), Libra Therapeutics emerged from a mission to address neurodegeneration, driven by the team's firsthand experience with its debilitating effects.[1][2][3][4] Isaac Veinbergs, Ph.D., serves as President and CEO, bringing over 25 years in biopharma R&D and leadership from roles at Acadia Pharmaceuticals, FoldRx, Amgen, Elan, Sanofi Genzyme, and others, where he advanced neurodegeneration programs to INDs and NDAs; his molecular pathology background from UCSD underscores the company's focus.[3][4] Early traction came via proprietary technologies, innovative assays from CROs like Axxam, and hit compounds from screening campaigns, enabling a "plug and play" virtual model that rapidly built a three-program pipeline without physical infrastructure.[1][2]
Libra rides the wave of lysosomal dysfunction and autophagy enhancement as key trends in neurodegeneration, where protein aggregation drives diseases like ALS and Parkinson's amid a market projected to exceed $50B by 2030 due to aging populations.[3][4] Timing aligns with advances in small molecule screening and virtual biotech models, reducing barriers for nimble players amid Big Pharma's neuroscience resurgence post-failures in traditional approaches.[1][2] Favorable forces include CRO globalization lowering costs and AI-driven discovery accelerating hits, positioning Libra to influence the ecosystem by validating biomarker strategies and potentially licensing assets to larger firms seeking disease-modifying therapies.[2]
Libra's Phase 1 entry for its TRPML1 program in 2025 marks a pivotal inflection, with pipeline expansion into ALS, Alzheimer's, and beyond likely drawing partnerships or further funding as biomarkers de-risk clinical readouts.[1][2] Trends like precision autophagy modulators and virtual biotechs will propel growth, evolving Libra's influence from early-stage innovator to potential acquirer in a neurodegeneration space hungry for breakthroughs. This cellular balance restoration hooks back to its founding ethos, promising tangible progress against unmet needs in brain health.[3][4]